KR850003402A - 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법 - Google Patents

2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법 Download PDF

Info

Publication number
KR850003402A
KR850003402A KR1019840006093A KR840006093A KR850003402A KR 850003402 A KR850003402 A KR 850003402A KR 1019840006093 A KR1019840006093 A KR 1019840006093A KR 840006093 A KR840006093 A KR 840006093A KR 850003402 A KR850003402 A KR 850003402A
Authority
KR
South Korea
Prior art keywords
alkyl
general formula
compound
phenyl
formula
Prior art date
Application number
KR1019840006093A
Other languages
English (en)
Other versions
KR860001818B1 (ko
Inventor
로렌스 라마티나 존
Original Assignee
테렌스 제이 갈라거
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테렌스 제이 갈라거, 화이자 인코포레이티드 filed Critical 테렌스 제이 갈라거
Publication of KR850003402A publication Critical patent/KR850003402A/ko
Application granted granted Critical
Publication of KR860001818B1 publication Critical patent/KR860001818B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

내용 없음

Description

2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 일반식(II)의 5-아세틸-2-아미노옥사졸을 물 존재하에 90℃ 내지 125℃ 범위의 온도에서 일반식 RR′NH의 아민과 반응시키고, 생성된 혼합물로 부터 목적하는 일반식(I)의 화합물을 분리시키고, 필요한 경우, 생성된 화합물을 적절한 산과 반응시켜 약제학적으로 허용되는 산부가염으로 전환시킴을 특징으로 하여 거의 순수한 형태의 다음 일반식(I)의 화합물 또는 그의 산부가염을 제조하는 방법.
    상기식에서, R은 수소 또는 (C1-C15)알킬이고, R′는 수소, (C1-C15)알킬, (C5-C8)시클로알킬, (C2-C15)알케닐, 페닐, 푸릴, 티에닐, (C7-C20)페닐알킬, 또는 할로, (C1-C3)알킬, (C1-C3)알콕시 또는 트리플루오로메틸에 의해 치환된 페닐 알킬이거나; R 및 R′는 이들이 부착된 질소원자와 함께 피페리딜그룹, (C1-C15)알킬 또는 (C7-C20)페닐 알킬에 의해 치환된 피페리딜 그룹, 또는 피롤리디닐 그룹을 형성한다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840006093A 1983-10-03 1984-10-02 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조 방법 KR860001818B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/538,233 US4554276A (en) 1983-10-03 1983-10-03 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US538233 1983-10-03

Publications (2)

Publication Number Publication Date
KR850003402A true KR850003402A (ko) 1985-06-17
KR860001818B1 KR860001818B1 (ko) 1986-10-24

Family

ID=24146051

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840006093A KR860001818B1 (ko) 1983-10-03 1984-10-02 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조 방법

Country Status (25)

Country Link
US (1) US4554276A (ko)
EP (1) EP0138464B1 (ko)
JP (1) JPS6094970A (ko)
KR (1) KR860001818B1 (ko)
AT (1) ATE47999T1 (ko)
AU (1) AU548268B2 (ko)
CA (1) CA1215985A (ko)
DD (1) DD232698A5 (ko)
DE (1) DE3480474D1 (ko)
DK (1) DK162222C (ko)
EG (1) EG16355A (ko)
ES (1) ES8601924A1 (ko)
FI (1) FI84479C (ko)
GR (1) GR80512B (ko)
HU (1) HU194186B (ko)
IE (1) IE57633B1 (ko)
IL (1) IL73104A (ko)
NO (1) NO170883C (ko)
NZ (1) NZ209740A (ko)
PH (1) PH21038A (ko)
PL (1) PL148590B1 (ko)
PT (1) PT79278B (ko)
SU (1) SU1342417A3 (ko)
YU (1) YU44058B (ko)
ZA (1) ZA847731B (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
IE58373B1 (en) * 1986-06-18 1993-09-08 Bloomfield Frederick Jacob 5-Lipoxygenase pathway inhibitors
WO1989000423A1 (en) * 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
MX14001A (es) * 1987-12-02 1993-06-01 Pfizer Procedimiento para preparar derivados de hidroxipirimidinas
US4910204A (en) * 1988-06-28 1990-03-20 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
DE68910288T2 (de) * 1988-12-14 1994-02-17 Pfizer Derivate von 5-Hydroxy- und 5-Methoxy-2-amino-pyrimidin als Inhibitoren der Interleukin-1-Produktion.
US5071852A (en) * 1988-12-14 1991-12-10 Pfizer Inc. Derivatives of 5-hydroxy and 5-methoxy 2-amino-pyrimidines as inhibitors of interleukin-1 production
US4940712A (en) * 1989-05-26 1990-07-10 Pfizer Inc. Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5248682A (en) * 1991-01-31 1993-09-28 Warner-Lambert Company 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5220025A (en) * 1992-02-24 1993-06-15 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
AU4566093A (en) * 1992-07-08 1994-01-31 Shell Internationale Research Maatschappij B.V. Piperidine derivatives
AU698313B2 (en) * 1994-03-14 1998-10-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
AU2001280445A1 (en) * 2000-06-23 2002-01-08 Vanderbilt University Novel chain-breaking antioxidants
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2260837A1 (en) * 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
DE102004054080A1 (de) * 2004-11-09 2006-05-11 Wella Ag Haut- oder Haarbehandlungsmittel mit Schutzeffekt
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
AU2009204360B2 (en) * 2008-01-04 2014-12-18 Src, Inc. The use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound and single dose compositions thereof
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
IL299845A (en) 2020-07-15 2023-03-01 Schabar Res Associates Llc Oral unit dose compounds consisting of ibuprofen and famotidine for the treatment of acute pain and to reduce the severity and/or risk of heartburn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000138A (en) * 1966-03-31 1976-12-28 Imperial Chemical Industries Limited Organic compounds and compositions containing them
US3932617A (en) * 1974-05-24 1976-01-13 The Upjohn Company Interferon induction
DE2814984A1 (de) * 1978-04-07 1979-10-18 Bayer Ag Pyrimidin(5)yl-(thiono)(thiol)- phosphor(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
IN153791B (ko) * 1979-03-10 1984-08-18 Soc D Etudes Prod Chimique
US4416885A (en) * 1979-11-02 1983-11-22 Huve Pierre M Use of isopropylaminopyrimidine in the chemotherapy of muscular dystrophy, myopathy and myotonia
OA07362A (fr) * 1980-10-27 1984-06-30 May & Baker Ltd Dérivés de la pyrimidine, leur procédé de préparation et les compositions les contenant.
US4435396A (en) * 1982-05-10 1984-03-06 Pfizer Inc. Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor

Also Published As

Publication number Publication date
YU169584A (en) 1987-02-28
JPH0528707B2 (ko) 1993-04-27
IE842494L (en) 1985-04-03
HU194186B (en) 1988-01-28
NZ209740A (en) 1987-04-30
DK472184A (da) 1985-04-04
AU3376884A (en) 1985-04-18
ZA847731B (en) 1986-05-28
GR80512B (en) 1985-02-01
YU44058B (en) 1990-02-28
FI843864L (fi) 1985-04-04
DE3480474D1 (de) 1989-12-21
DK472184D0 (da) 1984-10-02
JPS6094970A (ja) 1985-05-28
DK162222C (da) 1992-03-02
PL249833A1 (en) 1985-06-04
PL148590B1 (en) 1989-11-30
IE57633B1 (en) 1993-02-10
ES536499A0 (es) 1985-11-16
PT79278B (en) 1986-11-18
PH21038A (en) 1987-07-03
EG16355A (en) 1987-04-30
US4554276A (en) 1985-11-19
KR860001818B1 (ko) 1986-10-24
AU548268B2 (en) 1985-12-05
CA1215985A (en) 1986-12-30
IL73104A0 (en) 1984-12-31
EP0138464B1 (en) 1989-11-15
DK162222B (da) 1991-09-30
IL73104A (en) 1987-12-20
ATE47999T1 (de) 1989-12-15
DD232698A5 (de) 1986-02-05
EP0138464A2 (en) 1985-04-24
SU1342417A3 (ru) 1987-09-30
NO170883B (no) 1992-09-14
FI84479B (fi) 1991-08-30
NO170883C (no) 1992-12-23
ES8601924A1 (es) 1985-11-16
HUT35651A (en) 1985-07-29
EP0138464A3 (en) 1986-08-20
NO843968L (no) 1985-04-09
PT79278A (en) 1984-10-01
FI84479C (fi) 1991-12-10
FI843864A0 (fi) 1984-10-02

Similar Documents

Publication Publication Date Title
KR850003402A (ko) 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법
GB1422263A (en) 4-phenyl-piperidine compounds
KR840007412A (ko) 벤조-헤테로 고리 화합물의 제조방법
KR850006386A (ko) 아졸류의 제조방법
KR900016220A (ko) 매크로리드 조성물
KR830001947A (ko) 화합물의 제조방법
ES8609204A1 (es) Procedimiento de preparar derivados aminicos
KR840006475A (ko) 나프탈렌 유도체의 제조방법
KR840007587A (ko) 4-시아노피리다진의 제조방법
KR910016695A (ko) 4-(아미노메틸) 피페리딘 유도체, 그의 제조방법 및 치료에의 이용
KR850004585A (ko) 신규 아미노과니딘 유도체의 제조방법
KR840007579A (ko) 신규 니트로 알리파틱화합물의 제조방법
MY109628A (en) An improved proces for the preparation of substituted indoline derivatives
KR830005110A (ko) 플루오렌 유도체의 제조방법
KR830004210A (ko) 2-아미노-3-벤조일-페닐아세트아미드 및 환상 동족체
KR850001194A (ko) 화합물
KR870004038A (ko) 제초제 화합물의 제조방법
KR840007564A (ko) 치환된 벤질사이클로알케닐우레아 유도체의 제조방법
KR850003382A (ko) 디아릴인단-1,3-디온의 제조방법
KR850001903A (ko) 2,6-이중치환-1,4-디하이드로피리딘 유도체의 제조방법과 이것을 포함하는 약학적 조성물
KR850001165A (ko) 중추 신경계 활성을 갖는 피롤리디논의 제조방법
KR900700104A (ko) 항불안제
KR920002594A (ko) 5-이소티아졸아민 유도체
KR830005188A (ko) 혈당강하성 구아닐 아미딘의 제조방법
KR850005435A (ko) 3-알콕시-2-(n-피롤리디노)-n-피리미디닐-또는 n-피라지닐 프로필아민의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19930907

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee